LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

27.52 2.3

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.05

Max

27.79

Põhinäitajad
By Trading Economics
Sissetulek	-28M 22M
Müük	4.3M 244M
P/E Sektori keskmine	10.185 57.05
Aktsiakasum	1.08
Kasumimarginaal	9.224
Töötajad	293
EBITDA	-22M 52M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+52.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	49M 1.6B
Eelmine avamishind	25.22
Eelmine sulgemishind	27.52

Uudiste sentiment

By Acuity

50%

167 / 350 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. märts 2026, 20:20 UTC

Omandamised, ülevõtmised, äriostud

Infosys Agrees to Acquire Stratus

25. märts 2026, 23:58 UTC

Tulu

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25. märts 2026, 23:58 UTC

Tulu

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25. märts 2026, 23:57 UTC

Tulu

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25. märts 2026, 23:56 UTC

Tulu

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25. märts 2026, 23:41 UTC

Market Talk

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25. märts 2026, 23:41 UTC

Tulu

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25. märts 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Declines on Possible Technical Correction -- Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. märts 2026, 22:08 UTC

Market Talk

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25. märts 2026, 22:07 UTC

Tulu

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25. märts 2026, 21:58 UTC

Market Talk

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25. märts 2026, 21:37 UTC

Market Talk

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25. märts 2026, 21:14 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25. märts 2026, 21:13 UTC

Omandamised, ülevõtmised, äriostud

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25. märts 2026, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. märts 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

25. märts 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25. märts 2026, 20:31 UTC

Tulu

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25. märts 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

52.21% tõus

12 kuu keskmine prognoos

Keskmine 41.25 USD 52.21%

Kõrge 62 USD

Madal 25 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

167 / 350 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.